UNIQURE CEO Executes €19‑48 k Buy‑Sell Blitz, Betting on Gene‑Therapy Upswing in One Day Flash

Insider Activity Spotlight: Kapusta Matthew C’s Recent Transactions at UNIQURE NV

Why the Moves Matter On June 17, 2026, CEO and Managing Director Kapusta Matthew C executed a Rule 10b‑5‑1 sales‑plan purchase of 62,581 shares at €19.39, bringing his holdings to 723,239 shares. That same day he also sold 23,977 shares at €42.61, 6,023 shares at €43.70, 32,581 shares at €45.02, 56,929 shares at €43.43, 33,334 shares at €45.01, and 11,585 shares at €48.65. The rapid sequence of buys and sells—under a pre‑approved plan—suggests a strategic balance between capital preservation and liquidity management. For investors, the volume of shares traded (≈200,000 on a single day) signals that the CEO is actively managing his stake in line with company performance expectations.

Implications for Investors and the Company’s Outlook UNIQURE’s recent positive clinical data on AMT‑260 and the expected 2027 results are buoying the stock, reflected in a 66.9% weekly rise and 238.5% annual growth. The CEO’s sales plan, executed at a range of prices from €31.71 to €48.65, indicates a willingness to liquidate holdings during periods of price appreciation, potentially rewarding shareholders who hold through the upside. However, the simultaneous purchase at a low price suggests confidence in the company’s long‑term trajectory. Investors may interpret the activity as a vote of confidence coupled with prudent risk management—particularly important given the company’s negative P/E ratio and high volatility.

Profiling Kapusta Matthew C Kapusta has a long history of Rule 10b‑5‑1 transactions, consistently buying and selling in blocks that align with market peaks. In March 2026, he sold 14,581 shares at €9.06 and bought 70,600 shares at the same price, maintaining a stable net position of ~660,000 shares. Earlier in February, a sale of 12,378 shares at €23.86 reduced his stake to 639,076 shares, while a March purchase of 34,437 shares at €9.95 brought him back up to 604,639 shares. These patterns reveal a disciplined approach: large sales during high‑price windows and strategic purchases during dips. His recent activity mirrors this trend, underscoring a long‑term belief in UNIQURE’s gene‑therapy pipeline while preserving liquidity for other ventures.

Investor Takeaway The CEO’s trading activity, coupled with robust clinical milestones, paints a picture of a management team that is confident yet cautious. For shareholders, the lesson is clear: UNIQURE is navigating a volatile biotech landscape with a clear long‑term vision. Monitoring the CEO’s Rule 10b‑5‑1 plan will offer a window into future liquidity events and potential shifts in shareholder value.